Mark Reardon

The paper identifies hypoxia-induced ECM changes across cancers and shows they predict radiotherapy benefit.

This study identifies MMP11 as a blood-based biomarker for prostate cancer progression, regulated by the ALDH1A1-TGF-β1 signaling pathway.

This study uses a spheroid-on-chip system to analyze how interstitial fluid flow and hypoxia affect cancer gene expression and identifies potential biomarkers.

The paper shows that disease-associated genes are often the more evolutionarily constrained duplicates, challenging the compensatory model and introducing a new disease prediction model.